Whitehawk Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Three ADC programs are advancing, each targeting high-value cancer antigens with a proprietary, safer linker-payload system. Two programs are in clinical trials, with data expected in early 2027, and a third will enter the clinic in Q3. Cash reserves support operations into 2028.
-
The company is advancing three next-generation ADC programs with a unique, highly stable platform designed to improve efficacy and safety across multiple cancer types. Early clinical data for two programs are expected in 2027, with a third entering trials in 2026, all supported by strong capital efficiency and a focus on best-in-class outcomes.
-
Three ADC assets are advancing through clinical development, with two in Phase 1 and a third entering trials in Q3 2025. The platform offers improved potency, safety, and stability, with initial clinical data expected in H1 2027 and preclinical data releases planned for spring 2026.
Fiscal Year 2025
-
Three differentiated ADC programs are advancing to the clinic, targeting PTK7, MUC16, and SEZ6, with INDs planned by 2026 and initial clinical data expected in Q1 2027. The company is well-funded through early 2028 and aims to demonstrate best-in-class efficacy and safety across multiple solid tumor indications.
-
A next-generation ADC platform is advancing three assets targeting PTK7, MUC16, and SEZ6, with INDs for two programs expected this quarter and initial clinical data anticipated in early 2027. The platform demonstrates superior potency, stability, and safety, supported by strong financials and a focus on capital efficiency.
-
The company is advancing three ADC assets, with two IND filings planned for Q4 and a third in mid-2026. Lead programs target PCK7 and MUC16 with differentiated technology and biomarker strategies, aiming for broad impact in oncology. Cash reserves of $178M provide runway into early 2028.
-
Three ADC assets are advancing into clinical trials within the next year, targeting validated but less crowded tumor antigens in oncology. The programs leverage a best-in-class linker payload platform and aim to demonstrate superior efficacy and safety, with key data readouts expected in 2026 and 2027.
-
The discussion highlighted a robust ADC pipeline targeting PTK7, MUC16, and SEZ6, leveraging a next-generation linker-payload platform for improved efficacy and safety. The team emphasized disciplined capital allocation, competitive differentiation, and a clear clinical development roadmap with INDs planned through mid-2026.
-
Whitehawk Therapeutics, following its transition from Aadi Bioscience, is advancing three next-generation ADC programs targeting PTK7, MUC16, and SEZ6, leveraging a novel platform for improved efficacy and safety. IND filings are planned by mid-2026, with cash runway into 2028.
-
WhiteHWK Therapeutics has relaunched with $250 million in capital, licensing three next-generation ADCs from Hangzhou DAC and WuXi Biologics. The company’s proprietary platform emphasizes stability and intracellular payload release, with clinical programs targeting PTK7, MUC16, and SEZ6 set to enter trials over the next year.
-
Three major transactions—FYARRO sale, ADC in-licensing, and $100M PIPE—fund a strategic pivot to a next-gen ADC oncology pipeline. INDs for PTK7, MUC16, and SEZ6 assets are planned within 18 months, leveraging advanced linker technology and a strengthened leadership team.
Fiscal Year 2024
-
Completed transformation to an ADC-focused company with three in-licensed assets and strong cash runway into 2028. FYARRO sales grew prior to divestiture, and three INDs are targeted within 15 months, supported by a strengthened leadership team.
-
Announced sale of FYARRO for $100M, $100M PIPE financing, and in-licensing of three ADC assets from WuXi Biologics, transforming the pipeline to focus on next-generation ADCs targeting PTK7, MUC16, and SEZ6. Strong capital position supports clinical development into late 2028.
-
Q2 2024 saw FYARRO sales rise 15% sequentially, with strong demand and $78.6M in cash on hand. PRECISION 1 is fully enrolled, with a key interim readout expected in Q3 2024, and additional trials in EEC and NET are progressing rapidly.
-
FYARRO maintains strong market share in PEComa with stable sales, while the tumor-agnostic PRECISION1 trial for TSC1/TSC2 mutations nears a key interim readout in Q3. Additional phase 2 studies in NETs and EEC are enrolling, with updates expected by year-end.